Recently, tandem peptide nanocomplexes (TPNCs) carrying CpG DNA (TLR9 agonists), which stimulate TAM inflammatory gene expression, were shown to suppress tumor growth and synergize with CTLA-4 inhibition in primary BC models [167], warranting investigation of this strategy for BCBMs. The gene discussed is CTLA4; the disease is neoplasm.